1. Introduction {#sec1}
===============

Arteriovenous (AV) fistulas are very useful for determining optimal blood flow for dialysis, but AV fistulas exposed to overflow are thought to increase cardiac output and cause high-output cardiac failure \[[@B1], [@B2]\].

Measurement of blood flow via an internal shunt was first developed by Krivitski et al., and the monitoring of blood flow via a shunt has since become widespread \[[@B3]\]. We use this technique to monitor the blood flow of AV fistulas at our hospital and correct overflow AV fistulas with surgery.

It is thought that the outflow vein of overflow AV fistulas bears a heavy load: as the vein is exposed to increased arterial flow, the wall dilates, triggering a vascular remodeling process. However, the molecular mechanisms by which the outflow vein is remodeled into a mature fistula remain unclear. By investigating venous remodeling in overflow AV fistulas, candidate genes important to the remodeling process can be discovered and their functional significance investigated. Thus, the identification of relevant genes involved in this process should provide insight into AV fistula maturation.

In this study, we performed a cDNA microarray analysis and compared segments of the venous walls of overflow AV fistulas from 6 hemodialysis patients with the normal cephalic veins of 4 other hemodialysis patients to determine whether there was any difference in their gene expression patterns.

2. Study Population {#sec2}
===================

From June 2009 to September 2010, 548 patients underwent hemodialysis at the Oyokyo Kidney Research Institute in Hirosaki, Japan. During that period, 10 patients underwent surgical ligation to correct an overflow AV fistula. When the operation was performed, we retained a sample of the wall of the overflow AV fistula ([Figure 1](#fig1){ref-type="fig"}). The AV fistula specimens were resected from the wall of the vein close to the AV fistula anastomosis. The study was approved by the Bioethics Committee of Oyokyo Kidney Research Institute, and all patients provided their informed consent to the procedure prior to it being performed.

3. Inclusion Criteria {#sec3}
=====================

The inclusion criteria were as follows: (1) blood access flow greater than 2.0 L/min measured by the color Doppler ultrasound (2) an AV fistula in the lower arm with a distal radio-cephalic anastomosis. In total, 6 patients had overflow AV fistulas that met these criteria. The backgrounds of these patients are detailed in [Table 1](#tab1){ref-type="table"}. We also obtained tissue samples from the lower arm distal cephalic veins of 4 new hemodialysis patients and used these as a control.

4. Methods {#sec4}
==========

As noted above, venous tissues were resected from a venous segment of an overflow AV fistula from 6 patients and from a normal cephalic vein from 4 other patients. The surgical specimens were immediately placed in test tubes containing RNAlater (see below for details).

Total RNA was extracted from the venous tissue samples, and gene expression between the 2 groups was compared using Whole Human Genome DNA microarray 44 K (Agilent Technologies, Santa Clara, California). The microarray data were analyzed with GeneSpring GX software and Ingenuity Pathway Analysis.

5. RNA Isolation {#sec5}
================

Surgical specimens were 0.5 cm or smaller in size and were initially stored in RNA later (Ambion, Austin, TX) overnight at 4 ± 3°C then at --80°C until RNA extraction. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer\'s instructions. The total RNA was further purified using the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA) and then extracted. The quantity and quality of the RNA were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA) and an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA).

6. cRNA Amplification and Labeling {#sec6}
==================================

Total RNA was amplified and labeled with Cyanine 3 (Cy3) as instructed by the manufacturer of the Agilent Low Input Quick Amp Labeling Kit, one-color (Agilent Technologies, Palo Alto, CA). Briefly, 100 ng of total RNA was reverse transcribed to double-strand cDNA using a poly dT-T7 promoter primer. The primer, template RNA, and quality-control transcripts of known concentration and quality were then denatured at 65°C for 10 min and incubated for 2 hours at 40°C with 5X First-Strand Buffer, 0.1 M DTT, 10 mM dNTP mix, and Affinity Script RNase Block Mix. The Affinity Script enzyme was inactivated at 70°C for 15 min. The resulting cDNA products were then used as templates for in vitro transcription to generate fluorescent cRNA. They were mixed with a transcription master mix in the presence of T7 RNA polymerase and Cy3-labeled CTP and incubated at 40°C for 2 hours. Labeled cRNAs were purified using Qiagen\'s RNeasy Mini spin columns and eluted in 30 *μ*L of nuclease-free water. After amplification and labeling, cRNA quantity and cyanine incorporation were determined using a Nanodrop ND-1000 spectrophotometer and an Agilent Bioanalyzer.

7. Sample Hybridization {#sec7}
=======================

For each hybridization, 1.65 *μ*g of Cy3-labeled cRNA was fragmented and hybridized onto an Agilent Human GE 4x44K v2 Microarray (Design ID: 026652) for 17 hours at 65°C. After washing, the microarrays were scanned using an Agilent DNA microarray scanner.

8. Microarray Data Analysis {#sec8}
===========================

The intensity values of each scanned feature were quantified using Agilent feature extraction software (version 10.7.3.1), which performs background subtractions. We only used features flagged as having no errors (present flags) and excluded features that were not positive, not significant, not uniform, not above background levels, saturated, or population outliers (marginal and absent flags). Normalization was performed using Agilent GeneSpring GX version 11.0.2. (per chip: normalization to the 75 percentile shift; per gene: normalization to median across all samples). There are 34,127 probes in total on the Agilent Human GE 4x44K v2 Microarray (Design ID: 026652), excluding control probes. The microarray data were submitted to NCBI GEO (<http://www.ncbi.nlm.nih.gov/geo/>), sample number \[GSE39488\].

The altered transcripts were quantified using a comparative method. We applied a *P* value \< 0.05 combined with a \>2-fold change in normalized intensity to identify genes with significantly different expression patterns.

9. Gene Ontology Analysis and Pathway Analysis {#sec9}
==============================================

The gene ontology analysis was performed using Agilent Technologies GeneSpring GX software (11.0.2). Pathway analysis was performed with GenMAPP 2.1 (<http://www.genmapp.org/>).

10. Results {#sec10}
===========

The cDNA microarray analysis revealed that 397 genes were upregulated and 456 were downregulated (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

The gene ontology analysis revealed that biological developmental processes and glycosaminoglycan binding were the most upregulated. In addition, most upregulation occurred extracellularly (Tables [4](#tab4){ref-type="table"}, [5](#tab5){ref-type="table"}, and [6](#tab6){ref-type="table"}).

The pathway analysis revealed that the TGF beta signaling pathway, cytokines and inflammatory response pathway, hypertrophy model, and the myometrial relaxation and contraction pathway were upregulated ([Table 7](#tab7){ref-type="table"}).

11. Discussion {#sec11}
==============

AV fistulas are very useful for determining the optimal blood flow for hemodialysis since satisfactory blood access flow is necessary for adequate hemodialysis. When stenotic lesions occur within the vascular system and blood flow is insufficient, a percutaneous transluminal angioplasty or some other intervention is performed. However, overflow AV fistulas increase cardiac output and cause high-output cardiac failure \[[@B1]\].

In the 2005 Japanese Society for Dialysis Therapy Guidelines for Vascular Access Construction and Repair for Chronic Hemodialysis, vascular access flow is said to lead to heart failure when the blood access flow is greater than 1.0--1.5 L/min or when the vascular access flow/cardiac output ratio is \>20% \[[@B1]\]. If the vascular access flow is clearly responsible for a decline in cardiac function, then it is necessary to intentionally constrict or occlude the vascular access \[[@B1]\]. Surveillance of blood flow in internal shunts by the Doppler echocardiography has become widespread and overflow AV fistulas are now actively treated. Several recent studies have noted the importance of histological changes in AV fistulas \[[@B4], [@B5]\].

Microarrays of vascular access have been reported in experimental animal models, but there have been no such analyses in humans \[[@B6]\]. In the present study, venous tissue samples were resected from overflow AV fistulas from 6 hemodialysis patients and from the normal cephalic veins of 4 other hemodialysis patients, and their gene expression patterns were compared.

It is interesting to note that zinc finger-containing transcription factors such as egr1, egr2, and egr3 and immediate early genes such as fos and jun, were found to be remarkably upregulated in the present study; egr1, egr 2, and egr 3 have been implicated in the proliferation and differentiation of many cell types \[[@B7], [@B8]\], and fos and jun have been linked to the regulation of angiogenesis \[[@B9]\]. Moreover, egr-1, c-jun, and c-fos have been linked to the regulation of free radical scavenging enzymes \[[@B10]--[@B13]\]. We also observed the upregulation of free radical scavenging enzyme activity in the walls of the overflow AV fistulas, which may reflect chronic reactive oxygen species formation in overflow AV fistulas.

The pathway analysis indicated that the TGF beta signaling pathway and cytokines and inflammatory response pathway were upregulated. This suggests that overflow AV fistulas may be implicated in chronic inflammation in hemodialysis patients.

Malnutrition, inflammation, and atherosclerosis (MIA syndrome) are common in end-stage renal disease (ESRD) patients, and inflammation has been identified as playing a key role in atherosclerotic cardiovascular disease. Proinflammatory cytokines are pivotal to the inflammation that is, associated with malnutrition and atherosclerosis in ESRD \[[@B14]\]. Our findings suggest that overflow AV fistulas may be implicated in MIA syndrome.

12. Conclusion {#sec12}
==============

Combining microarray results and pathway information available via the Internet provided biological insight into molecular changes in the venous walls of overflow AV fistulas. Despite the small sample size, our study findings suggest that overflow AV fistulas may be implicated in chronic inflammation in hemodialysis patients.

![(a) Photograph of overflow AV fistula. (b) Schematic of overflow AV fistula.](IJN2013-980923.001){#fig1}

###### 

Patient characteristics.

  Over flow AVF   Age   Gender   Cause of CRF   Patency period of AV fistula (months)   Blood flow (mL/min)
  --------------- ----- -------- -------------- --------------------------------------- ---------------------
  1               48    M        CGN            56                                      3790
  2               83    F        CGN            93                                      2760
  3               57    M        CGN            19                                      3280
  4               46    M        CGN            22                                      2710
  5               75    M        CGN            104                                     3520
  6               57    F        IgA            88                                      2340
                                                                                        
  Control                                                                               
  1               67    M        CGN            (−)                                     (−)
  2               68    F        CGN            (−)                                     (−)
  3               56    M        CGN            (−)                                     (−)
  4               80    F        CGN            (−)                                     (−)

###### 

Genes significantly upregulated in the remodeled vein compared to the control vein (top 30).

  Probe name      *P* value      FCAbsolute   Gene symbol
  --------------- -------------- ------------ -------------
  A_23_P106194    0.045653246    38.85        FOS
  A_23_P429998    0.021514166    27.22        FOSB
  A_24_P33895     0.001204797    25.26        ATF3
  A_23_P46936     1.36*E* − 05   24.77        EGR2
  A_23_P96158     0.002943707    24.55        KRT17
  A_23_P34915     0.001120758    23.39        ATF3
  A_23_P71037     0.004629572    21.98        IL6
  A_23_P46429     7.94*E* − 04   21.04        CYR61
  A_24_P882732    0.036205057    19.08        
  A_23_P97141     0.0211732      17.66        RGS1
  A_23_P323751    9.21*E* − 05   17.26        FAM83D
  A_33_P3316273   0.00369598     15.81        CCL3
  A_23_P216225    0.0219925      15.72        EGR3
  A_33_P3295203   0.001008955    15.65        HAS1
  A_23_P131208    2.92*E* − 04   14.26        NR4A2
  A_23_P214080    0.00224604     13.9         EGR1
  A_33_P3214105   8.77*E* − 04   13.44        ATF3
  A_33_P3390793   0.004063138    13.41        TRIM36
  A_33_P3354607   0.001234311    13.09        CCL4
  A_23_P79518     0.006241249    12.95        IL1B
  A_23_P1331      0.001146301    11.08        COL13A1
  A_23_P110569    7.10*E* − 04   10.2         TRIM36
  A_23_P166408    0.003698398    10.04        OSM
  A_32_P76627     1.51*E* − 04   10.02        
  A_23_P207564    0.00151482     9.94         CCL4
  A_33_P3299066   0.001036557    9.61         NR4A2
  A_33_P3214393   0.008276591    9.56         
  A_33_P3413741   0.032112285    9.53         OXTR
  A_33_P3271594   0.001451045    9.49         TRIM54
  A_24_P158089    0.003357552    8.93         SERPINE1

###### 

Genes significantly downregulated in the remodeled vein compared to the control vein (top 30).

  Probe name      FCAbsolute   *P* value      Gene symbol
  --------------- ------------ -------------- -------------
  A_23_P23783     18.99        0.009408315    MYOC
  A_23_P121545    14.63        6.67*E* − 04   GPM6A
  A_33_P3368193   10.96        2.33*E* − 05   PNLIPRP3
  A_32_P92489     8.79         0.004908097    PKD1L2
  A_24_P40626     8.15         0.011296479    GREM2
  A_33_P3221408   8.14         0.004285622    NTNG1
  A_23_P143526    7.15         0.004383178    S100B
  A_23_P136777    7.14         3.89*E* − 04   APOD
  A_23_P102331    7.10         0.003490915    SCN7A
  A_33_P3421923   7.03         0.001119926    CADM3
  A_23_P140384    7.00         0.026459113    CTSG
  A_33_P3363799   6.94         0.002682039    NCAM1
  A_24_P203134    6.80         0.024163503    DCAF12L1
  A_24_P280684    6.69         0.03005707     FBXO40
  A_23_P55544     6.51         0.004269639    CCBE1
  A_23_P73571     6.45         0.03981546     MUM1L1
  A_23_P212050    6.22         0.021448081    BCHE
  A_33_P3336557   6.12         1.20*E* − 04   
  A_23_P121676    6.07         0.014616995    CXXC4
  A_23_P204885    6.01         0.007333652    PCDH20
  A_23_P64919     5.92         0.012492463    RERGL
  A_23_P422911    5.81         6.12*E* − 04   HS6ST3
  A_23_P146233    5.79         0.01808302     LPL
  A_23_P110624    5.76         0.003615111    CTNND2
  A_23_P45185     5.69         0.00549277     FIGF
  A_23_P110764    5.65         0.009343005    MYOT
  A_23_P114862    5.41         0.039056532    ANGPTL7
  A_23_P39251     5.31         9.92*E* − 04   PLIN5
  A_23_P111402    5.28         0.008291814    RSPO3
  A_33_P3400763   5.26         0.038730744    PLIN4

###### 

Statistically overrepresented GO terms in the biological process category (*P* \< 0.001).

  Biological process                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- --------------- ----- ------ ------ ------
  [GO:0032502](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0032502)                         Developmental process                                      2.100*E* − 11   77    29.8   3077   17.9
  [GO:0007275](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0007275)                         Multicellular organismal development                       1.340*E* − 10   67    26.0   2810   16.3
  [GO:0010033](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0010033)                         Response to organic substance                              3.530*E* − 10   40    15.5   698    4.1
  [GO:0001568](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0001568)                         Blood vessel development                                   9.230*E* − 10   21    8.1    231    1.3
  [GO:0048514](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048514)                         Blood vessel morphogenesis                                 1.250*E* − 09   19    7.4    198    1.1
  [GO:0001944](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0001944)                         Vasculature development                                    1.250*E* − 09   21    8.1    238    1.4
  [GO:0048545](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048545)                         Response to steroid hormone stimulus                       1.360*E* − 09   23    8.9    183    1.1
  [GO:0001525](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0001525)                         Angiogenesis                                               2.930*E* − 09   18    7.0    139    0.8
  [GO:0009653](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009653)                         Anatomical structure morphogenesis                         4.930*E* − 09   30    11.6   1125   6.5
  [GO:0016265](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0016265)                         Death                                                      5.110*E* − 09   39    15.1   663    3.8
  [GO:0048646](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048646)                         Anatomical structure formation involved in morphogenesis   5.950*E* − 09   18    7.0    306    1.8
  [GO:0008219](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0008219)                         Cell death                                                 1.280*E* − 08   37    14.3   658    3.8
  [GO:0042221](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0042221)                         Response to chemical stimulus                              1.280*E* − 08   53    20.5   1264   7.3
  [GO:0048856](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048856)                         Anatomical structure development                           1.320*E* − 08   42    16.3   2437   14.1
  [GO:0006950](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0006950)                         Response to stress                                         2.080*E* − 08   51    19.8   1642   9.5
  [GO:0048731](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048731)                         System development                                         3.600*E* − 08   38    14.7   2284   13.3
  [GO:0032570](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0032570)                         Response to progesterone stimulus                          7.370*E* − 08   9     3.5    21     0.1
  [GO:0006915∣GO:0008632](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0006915)              Apoptosis                                                  1.340*E* − 07   31    12.0   541    3.1
  [GO:0012501∣GO:0016244](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0012501)              Programmed cell death                                      1.900*E* − 07   31    12.0   549    3.2
  [GO:0042981](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0042981)                         Regulation of apoptosis                                    2.470*E* − 07   35    13.6   796    4.6
  [GO:0032501∣GO:0050874](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0032501)              Multicellular organismal process                           3.190*E* − 07   70    27.1   4154   24.1
  [GO:0043067∣GO:0043070](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0043067)              Regulation of programmed cell death                        3.190*E* − 07   35    13.6   804    4.7
  [GO:0010941](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0010941)                         Regulation of cell death                                   3.310*E* − 07   35    13.6   807    4.7
  [GO:0009887](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009887)                         Organ morphogenesis                                        3.510*E* − 07   26    10.1   685    4.0
  [GO:0009628](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009628)                         Response to abiotic stimulus                               5.270*E* − 07   16    6.2    357    2.1
  [GO:0009725](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009725)                         Response to hormone stimulus                               5.390*E* − 07   23    8.9    358    2.1
  [GO:0048519∣GO:0043118](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048519)              Negative regulation of biological process                  6.290*E* − 07   39    15.1   1756   10.2
  [GO:0009719](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009719)                         Response to endogenous stimulus                            7.450*E* − 07   24    9.3    391    2.3
  [GO:0009605](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009605)                         Response to external stimulus                              7.730*E* − 07   32    12.4   869    5.0
  [GO:0048513](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048513)                         Organ development                                          1.510*E* − 06   34    13.2   1682   9.8
  [GO:0009607](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009607)                         Response to biotic stimulus                                2.160*E* − 06   23    8.9    385    2.2
  [GO:0070482](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0070482)                         Response to oxygen levels                                  3.460*E* − 06   14    5.4    137    0.8
  [GO:0009266](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009266)                         Response to temperature stimulus                           3.950*E* − 06   9     3.5    86     0.5
  [GO:0050896∣GO:0051869](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0050896)              Response to stimulus                                       6.040*E* − 06   89    34.5   3356   19.5
  [GO:0048523∣GO:0051243](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048523)              Negative regulation of cellular process                    8.220*E* − 06   38    14.7   1606   9.3
  [GO:0009408∣GO:0006951](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009408)              Response to heat                                           8.220*E* − 06   9     3.5    61     0.4
  [GO:0006928](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0006928)                         Cellular component movement                                1.200*E* − 05   14    5.4    450    2.6
  [GO:0050793](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0050793)                         Regulation of developmental process                        1.590*E* − 05   8     3.1    670    3.9
  [GO:0048869](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048869)                         Cellular developmental process                             1.600*E* − 05   24    9.3    1641   9.5
  [GO:0022603](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0022603)                         Regulation of anatomical structure morphogenesis           2.530*E* − 05   5     1.9    228    1.3
  [GO:0051239](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051239)                         Regulation of multicellular organismal process             2.860*E* − 05   7     2.7    924    5.4
  [GO:0007565](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0007565)                         Female pregnancy                                           3.100*E* − 05   13    5.0    104    0.6
  [GO:0030154](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0030154)                         Cell differentiation                                       4.450*E* − 05   24    9.3    1576   9.1
  [GO:0042127](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0042127)                         Regulation of cell proliferation                           4.830*E* − 05   29    11.2   773    4.5
  [GO:0001666](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0001666)                         Response to hypoxia                                        6.420*E* − 05   14    5.4    131    0.8
  [GO:0008284](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0008284)                         Positive regulation of cell proliferation                  7.720*E* − 05   16    6.2    410    2.4
  [GO:0048522∣GO:0051242](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048522)              Positive regulation of cellular process                    7.720*E* − 05   34    13.2   1806   10.5
  [GO:0051789](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051789)                         Response to protein stimulus                               8.360*E* − 05   11    4.3    96     0.6
  [GO:0048518∣GO:0043119](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0048518)              Positive regulation of biological process                  9.260*E* − 05   35    13.6   1982   11.5
  [GO:0043627](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0043627)                         Response to estrogen stimulus                              1.000*E* − 04   12    4.7    98     0.6
  [GO:0009991](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009991)                         Response to extracellular stimulus                         1.000*E* − 04   6     2.3    204    1.2
  [GO:0042493∣GO:0017035](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0042493)              Response to drug                                           1.770*E* − 04   17    6.6    213    1.2
  [GO:0043066](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0043066)                         Negative regulation of apoptosis                           1.790*E* − 04   19    7.4    345    2.0
  [GO:0043069∣GO:0043072](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0043069)              Negative regulation of programmed cell death               2.200*E* − 04   19    7.4    350    2.0
  [GO:0051384](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051384)                         Response to glucocorticoid stimulus                        2.200*E* − 04   10    3.9    70     0.4
  [GO:0050789∣GO:0050791](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0050789)              Regulation of biological process                           2.440*E* − 04   109   42.2   7200   41.8
  [GO:0060548](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0060548)                         Negative regulation of cell death                          2.570*E* − 04   19    7.4    354    2.1
  [GO:0051707∣GO:0009613∣GO:0042828](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051707)   Response to other organism                                 2.770*E* − 04   17    6.6    300    1.7
  [GO:0040011](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0040011)                         Locomotion                                                 2.800*E* − 04   16    6.2    415    2.4
  [GO:0009611∣GO:0002245](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0009611)              Response to wounding                                       2.800*E* − 04   21    8.1    507    2.9
  [GO:0031960](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0031960)                         Response to corticosteroid stimulus                        3.860*E* − 04   10    3.9    75     0.4
  [GO:0050794∣GO:0051244](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0050794)              Regulation of cellular process                             4.070*E* − 04   108   41.9   6938   40.3
  [GO:0014070](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0014070)                         Response to organic cyclic substance                       4.200*E* − 04   12    4.7    114    0.7
  [GO:0051128](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051128)                         Regulation of cellular component organization              5.900*E* − 04   6     2.3    466    2.7
  [GO:0065007](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0065007)                         Biological regulation                                      7.620*E* − 04   109   42.2   7592   44.1
  [GO:0051704∣GO:0051706](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0051704)              Multiorganism process                                      7.900*E* − 04   27    10.5   706    4.1
  [GO:0031099](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0031099)                         Regeneration                                               8.770*E* − 04   6     2.3    65     0.4
  [GO:0007610](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0007610)                         Behavior                                                   9.680*E* − 04   12    4.7    449    2.6

###### 

Statistically overrepresented GO terms in the molecular function category (*P* \< 0.01).

  Molecular function                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- --------------- ----- ------ ------ ------
  [GO:0005539](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005539)              Glycosaminoglycan binding                                  9.960*E* − 06   14    5.4    149    0.9
  [GO:0005515∣GO:0045308](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005515)   Protein binding                                            1.550*E* − 05   170   65.9   8104   47.0
  [GO:0001871](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0001871)              Pattern binding                                            3.120*E* − 05   14    5.4    164    1.0
  [GO:0030247](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0030247)              Polysaccharide binding                                     3.120*E* − 05   14    5.4    164    1.0
  [GO:0008201](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0008201)              Heparin binding                                            6.710*E* − 05   13    5.0    112    0.7
  [GO:0005126](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005126)              Cytokine receptor binding                                  7.930*E* − 05   4     1.6    177    1.0
  [GO:0005125](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005125)              Cytokine activity                                          2.200*E* − 04   12    4.7    193    1.1
  [GO:0005114](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005114)              Type II transforming growth factor beta receptor binding   1.143*E* − 03   4     1.6    7      0.0
  [GO:0008083](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0008083)              Growth factor activity                                     2.365*E* − 03   13    5.0    160    0.9
  [GO:0005102](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005102)              Receptor binding                                           3.106*E* − 03   24    9.3    873    5.1
  [GO:0030246](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0030246)              Carbohydrate binding                                       7.049*E* − 03   14    5.4    354    2.1

###### 

Statistically overrepresented GO terms in the cellular component category (*P* \< 0.01).

  Cellular component                                                                                                                                                           
  -------------------------------------------------------------------------------------------- -------------------------------------------- --------------- ---- ------ ------ ------
  [GO:0044421](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0044421)   Extracellular region part                    2.190*E* − 09   49   19.0   937    5.4
  [GO:0031012](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0031012)   Extracellular matrix                         7.420*E* − 07   25   9.7    339    2.0
  [GO:0005576](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005576)   Extracellular region                         3.880*E* − 06   69   26.7   1923   11.2
  [GO:0005615](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005615)   Extracellular space                          1.690*E* − 05   32   12.4   673    3.9
  [GO:0005578](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0005578)   Proteinaceous extracellular matrix           1.200*E* − 04   20   7.8    309    1.8
  [GO:0060205](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0060205)   Cytoplasmic membrane-bounded vesicle lumen   4.070*E* − 04   7    2.7    44     0.3
  [GO:0031983](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0031983)   Vesicle lumen                                5.660*E* − 04   7    2.7    46     0.3
  [GO:0031093](http://amigo.geneontology.org/cgi-bin/amigo/term-details.cgi?term=GO:0031093)   Platelet alpha granule lumen                 2.468*E* − 03   7    2.7    41     0.2

###### 

Pathway analysis results.

  Pathway name                                         LS_vs_control
  ---------------------------------------------------- ---------------
  Alpha6 beta4 integrin signaling pathway              0.793
  Androgen receptor signaling pathway                  0.528
  Apoptosis mechanisms                                 0.124
  B-cell receptor signaling pathway                    0.023
  G1 to S cell cycle control                           1
  Cell cycle                                           0.487
  Delta-Notch signaling pathway                        0.226
  DNA replication                                      1
  EGFR1 signaling pathway                              0.856
  FAS pathway and stress induction of HSP regulation   1
  **Focal Adhesion**                                   **0.003**
  G13 signaling pathway                                0.269
  G protein signaling pathways                         0.258
  Hedgehog signaling pathway                           1
  Apoptosis modulation by HSP70                        1
  Id signaling pathway                                 1
  IL-1 signaling pathway                               1
  IL-2 signaling pathway                               0.327
  IL-3 signaling pathway                               0.371
  IL-4 signaling pathway                               0.589
  IL-5 signaling pathway                               0.576
  IL-6 signaling pathway                               1
  IL-7 signaling pathway                               0.498
  IL-9 signaling pathway                               1
  Human insulin signaling                              0.387
  Integrin-mediated cell adhesion                      0.363
  Kit receptor signaling pathway                       0.051
  MAPK cascade                                         1
  MAPK signaling pathway                               0.011
  mRNA processing (*Homo sapiens*)                     0.014
  Notch signaling pathway                              0.191
  Ovarian infertility genes                            1
  p38 MAPK signaling pathway (BioCarta)                0.108
  Regulation of actin cytoskeleton                     0.834
  Eukaryotic transcription initiation                  0.511
  Signal transduction of S1P                           0.384
  Signaling of hepatocyte growth factor receptor       1
  T cell receptor signaling pathway                    0.243
  TGF-beta receptor signaling pathway                  0.095
  **TGF beta signaling pathway**                       **0**
  TNF-alpha/NF-*κ*B signaling pathway                  0.752
  Translation factors                                  0.368
  Wnt signaling pathway                                0.15
  Wnt signaling pathway                                0.051
  Acetylcholine synthesis                              1
  Alanine and aspartate metabolism                     ---
  Biogenic amine synthesis                             1
  Cholesterol biosynthesis                             0.644
  Eicosanoid synthesis                                 1
  Electron transport chain                             0.013
  Fatty acid beta oxidation 1                          0.403
  Fatty acid beta oxidation 2                          1
  Fatty acid beta oxidation 3                          1
  Beta oxidation meta MAPP                             0.264
  Fatty acid omega oxidation                           0.687
  Fatty acid biosynthesis                              0.426
  Glucocorticoid and mineralcorticoid metabolism       1
  Glutathione metabolism                               0.399
  Glycogen metabolism                                  0.261
  Glycolysis and gluconeogenesis                       0.235
  Heme biosynthesis                                    1
  TCA cycle                                            0.24
  Mitochondrial LC-fatty acid beta-oxidation           0.635
  Nuclear receptors in lipid metabolism and toxicity   0.389
  Nucleotide metabolism                                0.622
  Pentose phosphate pathway                            1
  Prostaglandin synthesis and regulation               1
  Statin pathway (PharmGKB)                            1
  Steroid biosynthesis                                 1
  Synthesis and degradation of ketone bodies           1
  Triacylglyceride synthesis                           0.419
  Tryptophan metabolism                                0.501
  Beta oxidation of unsaturated fatty acids            1
  Urea cycle and metabolism of amino groups            ---
  GPCRs, class A rhodopsin-like                        0.317
  GPCRs, class B secretin-like                         1
  GPCRs, class C metabotropic glutamate, pheromone     1
  GPCRs, other                                         1
  Matrix metalloproteinases                            0.652
  Monoamine GPCRs                                      1
  Nuclear receptors                                    1
  Nucleotide GPCRs                                     1
  Peptide GPCRs                                        0.081
  Cytoplasmic ribosomal proteins                       0.025
  Small ligand GPCRs                                   1
  ACE inhibitor pathway (*Homo sapiens*)               0.254
  Adipogenesis human                                   0.101
  Blood clotting cascade                               0.155
  Calcium regulation in the cardiac cell               0.431
  Circadian exercise                                   0.754
  Complement activation and classical pathway          0.646
  Complement activation and classical pathway          0.022
  **Cytokines and inflammatory response (BioCarta)**   **0**
  **Hypertrophy model**                                **0**
  Inflammatory response pathway                        0.054
  Irinotecan pathway (*Homo sapiens*)                  0.685
  Oxidative stress                                     0.402
  Proteasome degradation                               0.278
  **Myometrial relaxation and contraction pathways**   **0**
  Striated muscle contraction                          0.427

[^1]: Academic Editor: Alejandro Martín-Malo
